<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000969</url>
  </required_header>
  <id_info>
    <org_study_id>CPCRA 002</org_study_id>
    <secondary_id>11554</secondary_id>
    <nct_id>NCT00000969</nct_id>
  </id_info>
  <brief_title>A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy</brief_title>
  <official_title>A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate and compare the effectiveness and toxicity associated with didanosine ( ddI ) and&#xD;
      zalcitabine ( dideoxycytidine; ddC ) in patients with HIV infection who are intolerant of or&#xD;
      have failed zidovudine ( AZT ) therapy.&#xD;
&#xD;
      Alternative and less toxic treatments need to be investigated for the treatment of HIV&#xD;
      infection. Studies have shown that the dideoxynucleosides ddI and ddC may be effective&#xD;
      antiretroviral agents in the treatment of HIV-infected individuals. However, ddI and ddC have&#xD;
      yet to be compared on the basis of patient survival, drug tolerance, immunologic and&#xD;
      virologic effectiveness, and the incidence of opportunistic infection or opportunistic&#xD;
      malignancy. Results of this study will yield information regarding the relative therapeutic&#xD;
      benefits and toxicities of each drug while providing alternative treatment to patients who&#xD;
      are unable to tolerate or have had progression of disease while on AZT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alternative and less toxic treatments need to be investigated for the treatment of HIV&#xD;
      infection. Studies have shown that the dideoxynucleosides ddI and ddC may be effective&#xD;
      antiretroviral agents in the treatment of HIV-infected individuals. However, ddI and ddC have&#xD;
      yet to be compared on the basis of patient survival, drug tolerance, immunologic and&#xD;
      virologic effectiveness, and the incidence of opportunistic infection or opportunistic&#xD;
      malignancy. Results of this study will yield information regarding the relative therapeutic&#xD;
      benefits and toxicities of each drug while providing alternative treatment to patients who&#xD;
      are unable to tolerate or have had progression of disease while on AZT.&#xD;
&#xD;
      After baseline screening, patients are randomized to one of two treatment arms (ddI or ddC).&#xD;
      Subjects are evaluated biweekly for the first 4 weeks of study, at 2 months, and every other&#xD;
      month thereafter. Three dose levels of ddI (based on patient's weight at study entry) are&#xD;
      compared with two dose levels of ddC (also based on patient weight). Patients who reach a new&#xD;
      progression-of-disease primary endpoint after at least 12 weeks of treatment or a drug&#xD;
      intolerance endpoint have the option of switching over to the alternate study drug; however,&#xD;
      participants are encouraged to remain on their original drug assignment whenever possible.&#xD;
      For any switchover, patients must be off the originally assigned drug for at least 72 hours&#xD;
      before switching. Only one switchover is allowed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">September 1992</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>400</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zalcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Acyclovir (if patient is also receiving ddC, clinical monitoring should be more&#xD;
             frequent).&#xD;
&#xD;
          -  Analgesics, antiemetics, antidiarrheal agents, or other necessary treatment for&#xD;
             symptomatic therapy.&#xD;
&#xD;
          -  Interferons for maintenance therapy of Kaposi's sarcoma.&#xD;
&#xD;
          -  GM-CSF.&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Prophylaxis against Pneumocystis carinii pneumonia (PCP) if their absolute CD4+&#xD;
             lymphocyte count is &lt; 200 cells/mm3 at study entry. PCP prophylaxis for patient with&#xD;
             CD4+ counts between 200 and 300 cells/mm3 is at discretion of patient's primary&#xD;
             physician.&#xD;
&#xD;
          -  NOTE: There is potential interaction of ddI and dapsone.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Transfusion, erythropoietin.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Zidovudine (AZT) failure after having received a cumulative duration of at least 6&#xD;
             months.&#xD;
&#xD;
          -  AZT intolerance - rechallenge is not required for patients exhibiting = or &gt; grade III&#xD;
             cutaneous symptoms.&#xD;
&#xD;
          -  Diagnosis of AIDS or CD4+ = or &lt; 300 cells/mm3 OR AIDS-defining illness other than&#xD;
             Kaposi's sarcoma.&#xD;
&#xD;
          -  Willingness and ability to comply with protocol.&#xD;
&#xD;
          -  Informed consent must be obtained for all study participants in accordance with state&#xD;
             law, local IRB requirements, and 45 CFR Part 46. AMENDED 11/19/90 to include assent by&#xD;
             minors if they are physically able, in addition to consent by parents.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Any disorders for which the study drugs are contraindicated (didanosine (ddI)) is&#xD;
             contraindicated in renal impairment, heart disease, receiving renal dialysis.&#xD;
&#xD;
          -  Active opportunistic infection.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other antiretroviral agents.&#xD;
&#xD;
          -  Use of drugs associated with peripheral neuropathy or use of agents that may cause&#xD;
             pancreatitis including intravenous pentamidine and alcohol should be restricted or&#xD;
             avoided.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other concurrent antiretroviral clinical trials.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  History of pancreatitis, peripheral neuropathy, uncontrolled seizures, renal&#xD;
             impairment, heart disease, stage 2 or higher ADC.&#xD;
&#xD;
          -  Any other disorders for which the study drugs are contraindicated, i.e., ddI is&#xD;
             contraindicated in renal impairment, patients receiving renal dialysis, and heart&#xD;
             disease.&#xD;
&#xD;
          -  Receiving acute therapy for active AIDS defining opportunistic infection on&#xD;
             enrollment.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Didanosine (ddI).&#xD;
&#xD;
          -  Dideoxycytidine (ddC) .&#xD;
&#xD;
        Excessive alcohol use that, in investigator's opinion, puts patient at risk of developing&#xD;
        pancreatic disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaplan C</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Crane L</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Abrams D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Community Consortium of San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver CPCRA / Denver Public Hlth</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>802044507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hill Health Corp</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmington Hosp / Med Ctr of Delaware</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19899</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Med Ctr / Regional AIDS Program</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Alliance - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Comm AIDS Rsch Prog / Tulane Univ Med</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive AIDS Alliance of Detroit</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hosp</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Jersey Community Research Initiative</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>071032842</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Lebanon Hosp Ctr</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Directors Network of Region II</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem AIDS Treatment Group / Harlem Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland Veterans Adm Med Ctr / Rsch &amp; Education Grp</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>972109951</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond AIDS Consortium</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bjorling LE, Hodges JS. Rule-based ranking schemes for antiretroviral trials. Stat Med. 1997 May 30;16(10):1175-91. doi: 10.1002/(sici)1097-0258(19970530)16:103.0.co;2-g.</citation>
    <PMID>9179982</PMID>
  </reference>
  <reference>
    <citation>Hogan CH, Hodges JS, Mugglin A, Peterson PM, Abrams DI, Saravolatz L. The perils of visit-driven endpoints in antiretroviral trials. Int Conf AIDS. 1996 Jul 7-12;11(1):237 (abstract no TuB522)</citation>
  </reference>
  <reference>
    <citation>Fleming TR, Neaton JD, Goldman A, DeMets DL, Launer C, Korvick J, Abrams D. Insights from monitoring the CPCRA didanosine/zalcitabine trial. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S9-18.</citation>
    <PMID>7552519</PMID>
  </reference>
  <reference>
    <citation>Goldman AI, Carlin BP, Crane LR, Launer C, Korvick JA, Deyton L, Abrams DI. Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Feb 1;11(2):161-9. doi: 10.1097/00042560-199602010-00007.</citation>
    <PMID>8556398</PMID>
  </reference>
  <reference>
    <citation>Abrams D, Goldman A, Launer C, Korvick J, Crane L, Deyton L. Results of a randomized open-label comparison trial of ddI and ddC in HIV infected patients who are intolerant of or have failed ZDV therapy; CPCRA 002. The Terry Beirn Community Programs for Clinical Research on AIDS. Int Conf AIDS. 1993 Jun 6-11;9(1):67 (abstract no WS-B24-4)</citation>
  </reference>
  <reference>
    <citation>Abrams DI, Goldman AI, Launer C, Korvick JA, Neaton JD, Crane LR, Grodesky M, Wakefield S, Muth K, Kornegay S, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 1994 Mar 10;330(10):657-62. doi: 10.1056/NEJM199403103301001.</citation>
    <PMID>7906384</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Zalcitabine</keyword>
  <keyword>Didanosine</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Zalcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

